As Anti-angiogenesis Evolves Into Likely HCS Market, Kentucky Team Hopes to Build Assay | GenomeWeb

More than a decade after Judah Folkman suggested that anti-angiogenesis could be a new approach to treating cancer, drug makers have been trying to develop therapeutics that inhibit the supply of blood to solid tumors.

More recently, a small number of cell-based assay and high-content screening developers have been trying to apply their technologies and methodologies to the angiogenesis space in the hopes that pharmas will use their tools in drug discovery [see sidebar].

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.